The Effect Coenzyme Q10 on cardiac complacation after chemotherapy

Evaluation the efficacy of oral coenzyme Q10 supplement on protection of Anthracycline-induced cardiotoxicity in pediatric malignancies

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016101026390N3

Enrollment

Registered

2016-10-23

Start date

2016-09-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Lymphoblastic Leukemia. Condition 2: Hodgkin Lymphoma. Lymphoid leukaemia Hodgkin lymphoma

Interventions

Intervention 1: Patients Under supervision of Nutritionist, Oncologist and cardiologist for taking Coenzyme Q10 200 mg for 3 monthes will select. Intervention 2: Patients in control group will recieve

Treatment - Drugs

Placebo

Patients Under supervision of Nutritionist, Oncologist and cardiologist for taking Coenzyme Q10 200 mg for 3 monthes will select.

Patients in control group will recieve placebo in the same number of intervention group for three monthes.

Eligibility

Sex/Gender

All

Age

1 Years to 16 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age between 1 and 16 years old; normal kidney and liver function; malignancy and under treatment with antracyclines; LVEF deterioration between 30 and 40%. Exclusion criteria: food supplement or other dietary regimen; congenital heart disease; other systemic disease other than cancer.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Left Ventricular Chamber Volume. Timepoint: Before and after intervention. Method of measurement: Echocardiography.;Left Ventricular End Diastolic Diameter. Timepoint: Before and after intervention. Method of measurement: Echocardiography.;Left Ventricular End Systolic Diameter. Timepoint: Before and after intervention. Method of measurement: Echocardiography.;Left Ventricular Ejection Fraction. Timepoint: Before and after intervention. Method of measurement: Echocardiography.;Left Ventricular Fraction Shortening. Timepoint: Before and after intervention. Method of measurement: Echocardiography.;Electrocardiogram iterpretion. Timepoint: Before and after intervention. Method of measurement: Electrocardiogram.	—

Measure

Time frame

Left Ventricular Chamber Volume. Timepoint: Before and after intervention. Method of measurement: Echocardiography.;Left Ventricular End Diastolic Diameter. Timepoint: Before and after intervention. Method of measurement: Echocardiography.;Left Ventricular End Systolic Diameter. Timepoint: Before and after intervention. Method of measurement: Echocardiography.;Left Ventricular Ejection Fraction. Timepoint: Before and after intervention. Method of measurement: Echocardiography.;Left Ventricular Fraction Shortening. Timepoint: Before and after intervention. Method of measurement: Echocardiography.;Electrocardiogram iterpretion. Timepoint: Before and after intervention. Method of measurement: Electrocardiogram.

—

Secondary

Measure	Time frame
Weight. Timepoint: Before and after intervention. Method of measurement: Sensitive Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKaveh Jaseb

Ahwaz Jundishapur University of Medical Sciences

k_jaseb@yahoo.com+98 61 3374 3285

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026